Amantadine as Augmentation in Managing Opioid Withdrawal with Clonidine: a randomized controlled trial
,
Abstract
Objective: Withdrawal symptoms are a main reason of continuous use of opioid. This study compares the efficacy of augmentation of amantadine with clonidine in decreasing opioid withdrawal symptoms.
Methods: This double-blind randomized clinical trial was carried out in the detoxification and rehabilitation inpatient ward at Razi Hospital, Tabriz, Iran during 2012. The patients were randomly assigned to receive clonidine or clonidine plus amantadine; and withdrawal symptoms were evaluated in the admission day and 24, 48, and 72 hours later. Data were analyzed using SPSS by the 2*2 repeated analyses of variances (ANOVA).
Results: From the total of 69 participants, 30 patients completed the trial in each group. The severity of symptoms, however, had an increasing trend in both groups. Analysis of variance of the symptom severity score (by The Clinical Opiate Withdrawal Scale) revealed a significant group-time interaction, and the patients who were receiving amantadine experienced milder symptoms .
Conclusions: Treatment of opioid withdrawal symptoms with amantadine and clonidine would result in a better outcome compared with clonidine alone.
Assadi SM, Hafezi M, Mokri A, Razzaghi EM , Ghaeli P. Opioid detoxification using high doses of buprenorphine in 24 hours: a randomized, double blind, controlled clinical trial. J Subst Abuse Treat 2004; 27: 75-82.
Gold MS, Redmond DE, Jr. , Kleber HD. Clonidine blocks acute opiate-withdrawal symptoms. Lancet 1978; 2: 599-602.
Raith K, Hochhaus G. Drugs used in the treatment of opioid tolerance and physical dependence: a review. Int J Clin Pharmacol Ther 2004; 42: 191-203.
Bisaga A, Comer SD, Ward AS, Popik P, Kleber HD, Fischman MW. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology (Berl) 2001; 157: 1-10.
Sadock BJ. Sadock VA. Kaplan and Sadock's Comprehensive Textbook of psychiatry , 7th ed. Philadelphia: Lippincot Williams & Wilkins; 2000. p. 941-1057.
Kampman KM, Volpicelli JR, Alterman AI, Cornish J , O'Brien CP. Amantadine in the treatment of cocaine-dependent patients with severe withdrawal symptoms. Am J Psychiatry 2000; 157: 2052-2054.
Kampman KM, Volpicelli JR, Alterman AI, Cornish J , O'Brien CP. Amantadine in the treatment of cocaine-dependent patients with severe withdrawal symptoms. Am J Psychiatry 2000; 157: 2052-2054.
Callaghan RC, Cunningham JA. Gender differences in detoxification: predictors of completion and re-admission. J Subst Abuse Treat 2002; 23: 399-407.
Gerra G, Zaimovic A, Giusti F, Di Gennaro C, Zambelli U, Gardini S, et al. Lofexidine versus clonidine in rapid opiate detoxification. J Subst Abuse Treat 2001; 21: 11-17.
Franken IH, Hendriks VM. Predicting outcome of inpatient detoxification of substance abusers. Psychiatr Serv 1999; 50: 813-817.
Li X, Sun H, Marsh DC, Anis AH. Factors associated with pretreatment and treatment dropouts: comparisons between Aboriginal and non_aboriginal clients admitted to medical withdrawal management. Harm Reduct J 2013; 10: 38-40.
Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs 2003; 35: 253-259.
Gold MS, Pottash AL, Sweeney DR , Kleber HD. Efficacy of clonidine in opiate withdrawal: a study of thirty patients. Drug Alcohol Depend 1980; 6: 201-208.
Kahn A, Mumford JP, Rogers GA, Beckford H. Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital. Drug Alcohol Depend 1997; 44: 57-61.
Gowing L, Farrell M, Ali R, White JM. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev 2009: CD002024.
Gerra G, Marcato A, Caccavari R, Fontanesi B, Delsignore R, Fertonani G, et al. Clonidine and opiate receptor antagonists in the treatment of heroin addiction. J Subst Abuse Treat 1995; 12: 35-41.
Comer SD, Sullivan MA. Memantine produces modest reductions in heroin-induced subjective responses in human research volunteers. Psychopharmacology (Berl) 2007; 193: 235-245.
Kukanich B, Papich MG. Plasma profile and pharmacokinetics of dextromethorphan after intravenous and oral administration in healthy dogs. J Vet Pharmacol Ther 2004; 27: 337-341.
King GR, Joyner C, Ellinwood EH, Jr. Continuous or intermittent cocaine administration: effects of amantadine treatment during withdrawal. Pharmacol Biochem Behav 1994; 47: 451-457.
Kampman KM, Dackis C, Lynch KG, Pettinati H, Tirado C, Gariti P, et al. A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Drug Alcohol Depend 2006; 85: 129-137.
Huber TJ, Dietrich DE, Emrich HM. Possible use of amantadine in depression. Pharmacopsychiatry 1999; 32: 47-55.
Perez de los Cobos J, Duro P, Trujols J, Tejero A, Batlle F, Ribalta E, et al. Methadone tapering plus amantadine to detoxify heroin-dependent inpatients with or without an active cocaine use disorder: two randomised controlled trials. Drug Alcohol Depend 2001; 63: 187-195.
Mathews DC, Henter ID, Zarate CA. Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs 2012 Jul 9; 72:1313-33.
| Files | ||
| Issue | Vol 9 No 3 (2014) | |
| Section | Articles | |
| Keywords | ||
| Amantadine Clonidine Withdrawal Syndrome | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
